Antonella Cammarota
@acammarota.bsky.social
Medical Oncologist | GI & HPB tumours | Clinical Trials | Translational research
🇮🇹 @HumanitasMilano 🇪🇺 @EORTC
🇮🇹 @HumanitasMilano 🇪🇺 @EORTC
Reposted by Antonella Cammarota
On #ClinicalTrialsDay, meet the next generation driving #CancerResearch forward. 👩🏻⚕️
In this video, Ioannis, Jens, and Antonella share what it means to be part of the EORTC Early Career Investigator community.
Learn more: www.eortc.org/blog/2025/05...
▶️ youtu.be/cjPQDCxrZbI
In this video, Ioannis, Jens, and Antonella share what it means to be part of the EORTC Early Career Investigator community.
Learn more: www.eortc.org/blog/2025/05...
▶️ youtu.be/cjPQDCxrZbI
Meet the EORTC Early Career Investigators
YouTube video by EORTC
youtu.be
May 20, 2025 at 9:29 AM
On #ClinicalTrialsDay, meet the next generation driving #CancerResearch forward. 👩🏻⚕️
In this video, Ioannis, Jens, and Antonella share what it means to be part of the EORTC Early Career Investigator community.
Learn more: www.eortc.org/blog/2025/05...
▶️ youtu.be/cjPQDCxrZbI
In this video, Ioannis, Jens, and Antonella share what it means to be part of the EORTC Early Career Investigator community.
Learn more: www.eortc.org/blog/2025/05...
▶️ youtu.be/cjPQDCxrZbI
Reposted by Antonella Cammarota
Please have a look at our comment on #ICI and #TKI for unresectable #HCC published in @thelancetoncol.bsky.social @acammarota.bsky.social
Online: Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable #HepatocellularCarcinoma (APOLLO): a randomised, controlled, phase 3 trial
bit.ly/4m9pBEZ
bit.ly/4m9pBEZ
May 9, 2025 at 10:55 PM
Please have a look at our comment on #ICI and #TKI for unresectable #HCC published in @thelancetoncol.bsky.social @acammarota.bsky.social
Reposted by Antonella Cammarota
"Science is a career for anyone curious enough to ask why, and stubborn enough to keep on asking." Yes, love this
"Becoming a #Scientist: The Graphic Novel" goes through the stories of my amazing lab members. Every one has a unique pathway, overcoming personal challenges. They are an inspirational #team!
www.thegreatbritishbookshop.co.uk/products/bec...
www.thegreatbritishbookshop.co.uk/products/bec...
Becoming a Scientist
"Science changes the world every day. Curing diseases, designing super-computers, building green technology, creating wearable nanotechnology... You may know what science can do, but what do you know ...
www.thegreatbritishbookshop.co.uk
February 3, 2025 at 7:28 AM
"Science is a career for anyone curious enough to ask why, and stubborn enough to keep on asking." Yes, love this
Reposted by Antonella Cammarota
Only a subset of patients respond to immunotherapy
Why? Which ones?
We conducted an unbiased analysis of response biomarkers and found that hundreds of possible biomarkers collapse into five latent, orthogonal factors that underlie immunotherapy response.
www.nature.com/articles/s41...
Why? Which ones?
We conducted an unbiased analysis of response biomarkers and found that hundreds of possible biomarkers collapse into five latent, orthogonal factors that underlie immunotherapy response.
www.nature.com/articles/s41...
November 27, 2024 at 2:13 PM
Only a subset of patients respond to immunotherapy
Why? Which ones?
We conducted an unbiased analysis of response biomarkers and found that hundreds of possible biomarkers collapse into five latent, orthogonal factors that underlie immunotherapy response.
www.nature.com/articles/s41...
Why? Which ones?
We conducted an unbiased analysis of response biomarkers and found that hundreds of possible biomarkers collapse into five latent, orthogonal factors that underlie immunotherapy response.
www.nature.com/articles/s41...
Reposted by Antonella Cammarota
Nice work from my (ex 😥) fellow @acammarota.bsky.social 👏👏
Examining PD-L1 expression in RCTs of chemo vs. chemo-ICI in operable GEA we show:
✅Strong link between PD-L1 and pathological response.
✖️ Less so OS ..
www.esmogastro.org/article/S294...
Looking forward to MATTERHORN next year!
Examining PD-L1 expression in RCTs of chemo vs. chemo-ICI in operable GEA we show:
✅Strong link between PD-L1 and pathological response.
✖️ Less so OS ..
www.esmogastro.org/article/S294...
Looking forward to MATTERHORN next year!
PD-L1 as a response biomarker to chemotherapy plus immune checkpoint inhibitors in operable gastroesophageal adenocarcinoma: a meta-analysis of neoadjuvant clinical trials
Perioperative chemoimmunotherapy [i.e. chemotherapy plus immune checkpoint inhibitor
(ICI) (ChT–ICI)] is an investigational treatment for operable gastroesophageal adenocarcinoma
(GEA) with unclear ou...
www.esmogastro.org
November 29, 2024 at 6:28 AM
Nice work from my (ex 😥) fellow @acammarota.bsky.social 👏👏
Examining PD-L1 expression in RCTs of chemo vs. chemo-ICI in operable GEA we show:
✅Strong link between PD-L1 and pathological response.
✖️ Less so OS ..
www.esmogastro.org/article/S294...
Looking forward to MATTERHORN next year!
Examining PD-L1 expression in RCTs of chemo vs. chemo-ICI in operable GEA we show:
✅Strong link between PD-L1 and pathological response.
✖️ Less so OS ..
www.esmogastro.org/article/S294...
Looking forward to MATTERHORN next year!